Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma
A Phase II Open-label Study of SH L 749 in Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphomas
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Aichi
-
Nagoya-shi, Aichi, Japan, 464-8681
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 277-8577
-
-
Gunma
-
Maebashi-shi, Gunma, Japan, 371-8511
-
-
Ishikawa
-
Kanazawa-shi, Ishikawa, Japan, 920-8641
-
-
Kanagawa
-
Isehara-shi, Kanagawa, Japan, 259-1193
-
-
Kyoto
-
Kyoto-shi, Kyoto, Japan, 602-0841
-
-
Miyagi
-
Sendai-shi, Miyagi, Japan, 980-0872
-
-
Tokyo
-
Chuo-ku, Tokyo, Japan, 104-0045
-
Shinjuku-ku, Tokyo, Japan, 160-8582
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Platelet counts of >/= 100,000/mm3
- Absolute neutrophil counts of >/= 1,200/mm3
- Bone marrow involvement < 25%
Exclusion Criteria:
- Patients who received hematopoietic stem cell transplantation, including bone marrow transplantation, peripheral blood stem cell transplantation, etc.
- Patients presenting with marked bone marrow hypocellularity (any suspected bone marrow hypocellularity should be confirmed by bone marrow biopsy)
- Patients with previous myocardial infarction within the past 1 year, with heart disease that requires treatment or with pulmonary dysfunction
- Patients with serious concomitant diseases (cardiac failure, renal failure, etc.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm 1
|
0,3mCi/kg
0,4mCi/kg
|
|
Experimental: Arm 2
|
0,3mCi/kg
0,4mCi/kg
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Best overall response rates (the percentage of patients who achieved PR or better response)
Time Frame: After 9 weeks or 13 weeks
|
After 9 weeks or 13 weeks
|
|
The incidence of critical toxicity
Time Frame: During treatment period
|
During treatment period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety evaluation
Time Frame: During treatment period
|
During treatment period
|
|
Complete response (CR or CRu) rates
Time Frame: After 9 weeks or 13 weeks
|
After 9 weeks or 13 weeks
|
|
Progression-free survival (PFS)
Time Frame: After end of study
|
After end of study
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 91102
- 305618
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.